http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 08:33:56 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Zai+Lab+%28ZLAB%29+PT+Raised+to+%2436+at+JPMorgan/26985515.html JPMorgan analyst Anupam Rama raised the price target on Zai Lab (NASDAQ: ZLAB) to $36.00 (from $27.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Zai+Lab+%28ZLAB%29+PT+Raised+to+%2436+at+JPMorgan/26985515.html Thu, 27 Aug 2026 08:33:56 -0400 ZLAB http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Smiley+Joshua+L/26956450.html si-local-file:///var/storage/secattach/20260820/26956450.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Smiley+Joshua+L/26956450.html Thu, 20 Aug 2026 16:20:00 -0400 1ZLB O.34841441 ZLAB http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Smiley+Joshua+L/26956450.html si-local-file:///var/storage/secattach/20260820/26956450.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Smiley+Joshua+L/26956450.html Thu, 20 Aug 2026 16:20:00 -0400 1ZLB O.34841441 ZLAB http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Smiley+Joshua+L/26956450.html si-local-file:///var/storage/secattach/20260820/26956450.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Smiley+Joshua+L/26956450.html Thu, 20 Aug 2026 16:20:00 -0400 1ZLB O.34841441 ZLAB http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Chen+Yajing/26949395.html si-local-file:///var/storage/secattach/20260819/26949395.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Chen+Yajing/26949395.html Wed, 19 Aug 2026 13:51:00 -0400 1ZLB O.34841441 ZLAB http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Chen+Yajing/26949395.html si-local-file:///var/storage/secattach/20260819/26949395.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Chen+Yajing/26949395.html Wed, 19 Aug 2026 13:51:00 -0400 1ZLB O.34841441 ZLAB http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Chen+Yajing/26949395.html si-local-file:///var/storage/secattach/20260819/26949395.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Zai+Lab+Ltd++++++++++++++++++++++++++++Filed+by%3A+Chen+Yajing/26949395.html Wed, 19 Aug 2026 13:51:00 -0400 1ZLB O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html <p>Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.</p> <p>The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).</p> <p>In a prespecified subtype analysis, the primary endpoint was also met in IMNM patients alone, with a 14.8-point greater improvement http://www.streetinsider.com/FDA/Zai+Lab+and+argenx+report+Phase+3+trial+win+for+myositis+drug/26934063.html Mon, 17 Aug 2026 06:00:59 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html <ul class="bwlistdisc"> <li> <i>Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)</i> </li> <li> <i>Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM</i> </li> <li> <i>First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy</i> </li> </ul> <p> SHANGHAI &amp; CAMBRIDGE, Mass. &amp; AMSTERDAM--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext &amp; NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html Mon, 17 Aug 2026 06:00:00 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html <ul class="bwlistdisc"> <li> <i>Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)</i> </li> <li> <i>Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM</i> </li> <li> <i>First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy</i> </li> </ul> <p> SHANGHAI &amp; CAMBRIDGE, Mass. &amp; AMSTERDAM--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext &amp; NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html Mon, 17 Aug 2026 06:00:00 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html <ul class="bwlistdisc"> <li> <i>Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)</i> </li> <li> <i>Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM</i> </li> <li> <i>First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy</i> </li> </ul> <p> SHANGHAI &amp; CAMBRIDGE, Mass. &amp; AMSTERDAM--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext &amp; NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html Mon, 17 Aug 2026 06:00:00 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html <ul class="bwlistdisc"> <li> <i>Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)</i> </li> <li> <i>Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM</i> </li> <li> <i>First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy</i> </li> </ul> <p> SHANGHAI &amp; CAMBRIDGE, Mass. &amp; AMSTERDAM--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext &amp; NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html Mon, 17 Aug 2026 06:00:00 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html <ul class="bwlistdisc"> <li> <i>Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)</i> </li> <li> <i>Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM</i> </li> <li> <i>First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy</i> </li> </ul> <p> SHANGHAI &amp; CAMBRIDGE, Mass. &amp; AMSTERDAM--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext &amp; NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html Mon, 17 Aug 2026 06:00:00 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html <ul class="bwlistdisc"> <li> <i>Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)</i> </li> <li> <i>Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM</i> </li> <li> <i>First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy</i> </li> </ul> <p> SHANGHAI &amp; CAMBRIDGE, Mass. &amp; AMSTERDAM--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext &amp; NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html Mon, 17 Aug 2026 06:00:00 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html <ul class="bwlistdisc"> <li> <i>Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)</i> </li> <li> <i>Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM</i> </li> <li> <i>First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy</i> </li> </ul> <p> SHANGHAI &amp; CAMBRIDGE, Mass. &amp; AMSTERDAM--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext &amp; NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and http://www.streetinsider.com/Press+Releases/Zai+Lab+and+argenx+Announce+Positive+Topline+Results+from+Phase+3+ALKIVIA+Trial+of+Efgartigimod+in+Autoimmune+Myositis/26934049.html Mon, 17 Aug 2026 06:00:00 -0400 0QW0 1ZLB 9688 A.05323225 A.17875977 ARGX ARGX O.01402212 O.04870500 O.22443941 O.34841441 ZLAB